Alluvi, formerly BI 4744, offers a significant breakthrough in obesity therapy. This dual stimulator targeting both GLP-1 and GIP sites demonstrates impressive effectiveness in research studies, possibly exceeding https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/